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We define the optimal parameters for combination of cryotherapy (nitrous oxide) with chemotherapy (vinorelbine ditartrate, VNB)
treatment and characterise some of the signals involved for apoptosis activation. No advantage appeared when cryotherapy and VNB
were combined simultaneously compared to cryosurgery alone. In contrast, tumour volumes were reduced after a sequential
treatment schedule, where each individual treatment was separated by 48h. No significant benefit appeared when the sequential
treatment was separated by 24h, although some individual mice showed a good response. The sequence of treatment had no impact
on the observed tumour growth inhibition in mice. The number of apoptotic cells was significantly augmented in the sequential
treatment schedule where VNB was administered 48h before cryotherapy. In this sequential treatment, the number of apoptotic
cells correlated with heightened expression of the BH3-only Puma, Noxa and Bim-EL, at both the mRNA and protein levels. No
significant change in Bax, Bcl-xL and Bcl-2 mRNA expression was apparent, whereas Mcl-1 expression increased only slightly to a
much lower level than BH3-only mRNAs. Our data indicate that 48h sequential rather than simultaneous cryotherapy with VNB in
future cancer cryochemotherapy schedules will enhance the tumour response, and argue that VNB administration, 48h before
cryotherapy, will provoke apoptosis more efficiently.
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Cryosurgery, a treatment based on the cytotoxic effects of cold,
consists of therapeutically applying extremely low temperatures to
living tissues to destroy them. It represents a minimally invasive
surgical technique that has expanded in applicability in recent
years. In the treatment of lung cancers, it can be proposed as a
palliative option, mainly to relieve airway obstruction and improve
the patient’s respiratory functions. It is safe, efficient, inexpensive,
easy to perform and does not present any major side effect
(Maiwand and Homasson, 1995; Vergnon, 1999). Although
cryosurgery is a potent method of in situ tissue destruction, it
generally needs the support of adjunctive therapy, including
chemotherapy or radiotherapy, to increase the rate of cell death in
the peripheral zone of the cryolesion. In this area, less damaged
cells can repair themselves and survive, requiring further injury to
synergise lethality (Gage and Baust, 1998; Korpan, 2001; Baust
et al, 2004). Moreover, it is well known that vascular changes occur
in tissues after freezing, and it is assumed that the hypervascularity
observed enhances tissue radiosensitivity and allows a better drug
delivery to tumour cells (Vergnon, 1999).
In vitro, combination of cryotherapy and chemotherapy,
also so-called cryochemotherapy, has delivered promising results.
Mir and Rubinsky (2002) have reported increased cytotoxicity
in melanoma cells subjected to cryochemotherapy. The cells
were first exposed to  201C before bleomycin treatment and
compared to cells treated only with bleomycin. The effect was due
to cold-induced membrane disorganisation, allowing greater
bleomycin influx into cells. A similar advantage of cryo-
chemotherapy was noted in PC-3 prostate cancer cells (Clarke
et al, 2001). In vivo, Le Pivert et al (2004) showed beneficial
actions of cryosurgery and local chemotherapy in a model of
human prostate tumour xenografts in nude mice. In this study,
a single freeze/thaw cycle was applied to tumours, and
5-fluorouracil (5-FU) microcapsules were delivered at the outer
margins of frozen areas. This combined treatment produced
better inhibition of tumour growth for a longer period of time
than cryoablation or local 5-FU microcapsule administration
alone. Earlier, we also reported a model of human A549 lung
adenocarcinoma xenografts in SCID mice, where combination of
cryotherapy (nitrous oxide) with chemotherapy (vinorelbine
ditartrate; VNB) enhanced cell death by necrosis and apoptosis,
mainly during the early phase of treatments, and limited tumour
growth, as tumours subjected to cryochemotherapy presented
a significantly reduced volume compared with tumours
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sundergoing cryosurgery or chemotherapy alone (Forest et al,
2005a,b; Forest et al, 2006).
A wide range of current studies focus particularly on how cell
death occurs after cryosurgery. It has been well documented that
apoptosis is an important mechanism of cell death when
temperature does not fall low enough to kill cells through direct
ice rupture or necrosis (Gage and Baust, 1998; Baust et al, 2004).
However, the molecular mechanisms involved are not elucidated.
The Bcl-2 family of proteins stands among the more important
regulators of apoptosis, and consists of both pro- and anti-
apoptotic members, which are characterised by the presence of
different BH (Bcl-2 homology) domains (Adams and Cory, 2007).
The ratio between the proapoptotic and the prosurvival members
helps to determine, in part, the susceptibility of cells to apoptosis
(Korsmeyer et al, 1993). In addition, a subset of this family, the
BH3-only proteins, has been well recognised as cell death signal
transmitters and potent mediators of apoptosis. Among them,
Puma, Noxa and Bim are often associated with chemotherapy-
induced apoptosis (Oda et al, 2000; Yu et al, 2001; Willis et al,
2007).
The aims of this study were (1) to define the optimal
parameters of combined cryotherapy and VNB treatment in
a model of lung adenocarcinoma xenografted into SCID
mice and (2) to characterise the molecular signalling of apoptosis
after these treatment schedules. For these purposes, we
compared the ability of different treatment protocols to induce
cell death and investigated the involvement of some Bcl-2 family
members, including Puma, Noxa, Bim-EL, Bax, Bcl-2, Bcl-xL
and Mcl-1.
MATERIALS AND METHODS
Experimental model
The A549 cell line, derived from a human lung adenocarcinoma,
was purchased from the American Type Culture Collection
(Manassas, VA, USA). The cells were maintained in culture at
371C in a humidified 5% CO2 atmosphere, in Ham’s F-12 medium
containing 2mML-glutamine (Gibco-BRL Life Technologies, Grand
Island, NY, USA) and supplemented with 10% foetal bovine serum
(Wisent Inc., Montreal, QC, Canada), 1.5gl
 1 sodium bicarbonate
(Gibco-BRL Life Technologies), 10000Uml
 1 penicillin (Wisent
Inc.) and 10mgml
 1 streptomycin (Wisent Inc.). Male SCID mice
(2–3 weeks old, 22–24g body weight) were supplied by Charles
River Laboratory Inc. (Wilmington, MA, USA) and housed in
sterile cages. They were fed autoclaved food and sterile water ad
libitum. For inoculation into SCID mice, the A549 cells were
trypsinised, washed and resuspended in sterile phosphate-buffered
saline (PBS, Wisent Inc.). The mice were injected subcutaneously
with this suspension (10
7 cells in 0.2ml), in the dorsal region,
bilaterally. When the tumours reached a volume of about 0.8cm
3,
the mice were treated. All operative procedures and animal
care conformed strictly to Canadian Council on Animal Care
guidelines.
Cryosurgery and chemotherapy
Eight experimental groups of three mice each were allocated
depending on the control or treatment regimen: (1) no treatment
(control group), (2) cryotherapy only (cryotherapy group),
(3) chemotherapy only (chemotherapy group), (4) cryotherapy
and chemotherapy simultaneously (cryochemotherapy group),
(5) cryotherapy followed by chemotherapy after 24h (cryo/24/
chemotherapy group), (6) chemotherapy followed by cryotherapy
after 24h (chemo/24/cryotherapy group), (7) cryotherapy followed
by chemotherapy after 48h (cryo/48/chemotherapy group) and (8)
chemotherapy followed by cryotherapy after 48h (chemo/48/
cryotherapy group). Cryotherapy was carried out with a nitrous
oxide cryoprobe, 3mm in diameter (Erbe Inc., Tu ¨bingen,
Germany). The Joule–Thomson effect allowed us to attain
temperatures ranging from  30 to  401C in tissues. After an
incision was made in the tumour, the cryoprobe was placed in
contact with it for three cycles of rapid freezing/thawing (20/20s
each). Chemotherapy consisted of a single intravenous injection
of VNB (Navelbine, Mayne Pharma Inc., Montreal, QC, Canada),
a vinca alkaloid commonly used in lung cancer treatment. A
clinically equivalent dose (4.8mgkg
 1) was injected into the tail
vein of mice previously anesthetised with isoflurane 2%. The
animals were then euthanised at variable time points before
(control) and after therapy, at 2, 8, 24, 48h, 4, 8, 14 and 21 days
(n¼3 for each point), and then tumours were excised. They were
sliced along the axis of the cryoprobe impact site. One-half of the
tumours was frozen directly in liquid nitrogen and kept for future
RNA extraction, and the other half was frozen in liquid nitrogen
but in the presence of optimal cutting temperature medium (Ted
Pella Inc., Redding, CA, USA) for future morphological and
immunohistochemical staining.
Kinetics of tumour growth
To evaluate the effects of the different treatments on tumour
growth, tumour volume (TV) was determined as follows: TV¼L 
W H, where L was the length, W the width and H the height of
the tumour, measured with a caliper. Relative tumour volume
(RTV) was then quantitated according to the formula RTV¼TVx/
TV0, where TVx corresponds to TV at day x, and TV0 to TV at day
0, before treatment.
Immunohistochemical staining
Frozen sections were exposed to standard haematoxylin–eosin–
saffron coloration to analyse tissue morphology. Necrosis,
estimated by a clinical pathologist in terms of a ratio between
the surface of necrotic areas and that of the whole tumour, was
expressed as percentages. Other tissue sections were fixed and
permeabilised by incubation in a 50% acetone – 50% methanol
solution for 3min at room temperature. Tissue sections were
washed with PBS and stained in Vectastain ABC-Alkaline
Phosphatase Universal and Alkaline Phosphatase Substrate kits
(Vector Laboratories Inc., Burlingame, CA, USA), according to
the manufacturer’s instructions. The primary antibodies used
were anti-active caspase-3 rabbit pAb 559565 (BD Biosciences
Pharmingen, Mississauga, ON, Canada) at 1:1000 dilution, anti-
Puma rabbit pAb PC686 (EMD-Biosciences-Calbiochem Inc., La
Jolla, CA, USA) at 1:50 dilution, anti-Noxa mouse mAb 114C307
(EMD-Biosciences-Calbiochem Inc.) at 1:50 dilution, anti-Bim
rabbit pAb 202000 (BD Biosciences Pharmingen) at 1:50 dilution
and anti-Bax mouse mAb Ab-2 (EMD-Oncogene Research Inc., San
Diego, CA, USA) at 1:50 dilution. After staining, slices were
washed with PBS, mounted with Vectashield (Vector Laboratories
Inc.) and images were generated with a Nikon Optiphot-2
microscope equipped and mounted with a thermoelectrically
cooled CCD camera (Model DC330E, DageMTI Inc., Michigan
City, IN, USA) hooked up to a PC computer. Images were analysed
with Clemex Vision software (Version 3.0.036, Clemex, Longueuil,
QC, Canada), and quantitative data on caspase-3 active fragment
were based on integrated volume values defined as intensity
(%) area (mm
2).
RNA isolation, reverse transcription and quantitative
real-time polymerase chain reaction (QRT–PCR)
RNA was extracted from frozen tissues in Trizol reagent
(Invitrogen Corp., Burlington, ON, Canada) according to the
manufacturer’s instruction. cDNA was synthesised with 1mg RNA
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sper sample by the SuperScript first-strand synthesis system
(Invitrogen Corp.). The cDNA was then amplified by QRT–PCR
in Rotor Gene (Model RG-3000A, Corbett Res., Mortlake, Australia)
with QuantiTect SYBR Green kits (Qiagen, Missisauga, ON, Canada)
in a final volume of 25ml. The primer pairs were Puma: 50-TGGA
CTCAGCATCGGAAGGT-30 (forward), 50-GCACCAGCACAACAG
CCTTT-30 (reverse), Noxa: 50-TTCGTGTTCAGCTCGCGTCC-30
(forward), 50-CTCGGTTGAG CGTTCTTGCG-30 (reverse), Bim-EL:
50-TGATGTAAGTTCTGAAGTGTG-30 (forward), 50-CTGGGAGGA
TCTTCTCATAA-30 (reverse), Bax: 50-AACTGGTGCTCAAGGCC
CTG-30 (forward), 50-GGGTGAGGAGGCTTGAGGAG-30 (reverse),
Bcl-2: 50-TTTGAGTTCG GTGGGGTCATG-30 (forward), 50-TCACTT
GTGGCTCAGATAGGC-30 (reverse), Bcl-xL: 50-ATCAATGGCAACC
CATCCTGG-30 (forward), 50-TTGTCTACGCTTTCCACGCAC-30
(reverse), Mcl-1: 50-GCTGCATCGAACCATTAGCAG-30 (forward),
50-TATGCCAAACC AGCTCCTACT-30 (reverse), b-actin: 50-ACTCT
TCCAGCCTTCCTTCC-30 (forward), 50-GTACTTGCGCTCAGGAGG
AG-30 (reverse). Cycling conditions were initiated with denatura-
tion for 15min at 951C, followed by 40 cycles of denaturation (951C
for 15s), annealing (581C for Puma, 591C for Noxa and Bax, 511C
for Bim-EL, 601C for Bcl-2, Bcl-xl and Mcl-1, 30s) and extension
(721C for 30s). Messenger RNAs (mRNAs) were quantitated
according to the Pfaffl mathematical model (Pfaffl, 2001). The
amount of targeted mRNAs was normalised to endogenous
reference mRNA (b-actin), and the data on treated tumours were
expressed relative to untreated tumours at day 0. The results are the
means of three independent experiments, each carried out in
duplicate.
Statistical analysis
Statistical analyses were carried out by two-way analysis of
variance with GraphPad Prism software (version 4.0c; San Diego,
CA, USA) and P40.05 values were considered as non-significant
(n.s.). All statistical analyses are provided online in the
Supplemental Data section.
RESULTS
Kinetics of tumour growth
This study compared the kinetics of tumour growth after
individual, simultaneous and sequential combination of cryo-
therapy and VNB treatment, in human A549 lung adenocarcinoma
xenograft-bearing SCID mice (Figure 1 and Supplementary Data).
At the concentration (4.8mgkg
 1) used in this study, the slight
difference observed in RTVs of mice treated with VNB only
compared with untreated controls was not statistically significant.
In contrast, cryotherapy alone produced a significant effect, with
RTVs much reduced than in untreated mice. Simultaneous
exposures to cryotherapy and VNB (cryochemotherapy) achieved
a very similar outcome on tumour growth as in mice subjected
only to cryotherapy. RTVs in mice undergoing cryotherapy alone
or simultaneous combination appeared stable for 3 days post-
treatment, but increased steadily thereafter, indicating that the
actions of these therapies were only partial. In the sequential
combination schedules, a marked and significant effect on tumour
growth was apparent when each treatment was separated by 48h.
Although some individual mice showed a good response when
each individual treatment was separated by 24h, the overall
differences between these groups and the simultaneous combina-
tion schedule were not statistically significant. Moreover, the
sequence of each treatment in these sequential combination
protocols had no major influence on the kinetics of tumour
growth inhibition. Interestingly, the 48h sequential combination
schedules also achieved a strong inhibition of tumour growth in
mice for a longer period of time. All statistical analyses are
provided in Supplementary Data.
Cell death induction
To investigate the mode and relative amount of cell death after
the different treatments and schedules, morphological assignment
of necrosis was blind-performed by a pathologist experienced
in Haematoxylin–Eosin–Saffron staining of tumour samples
with routinely deployed clinical criteria, and apoptosis was
determined by the presence of active caspase-3 proteolytic
fragment under immunohistochemical staining. Despite individual
variations within mice, the relative amount of necrosis was
generally low, ranging from 5 to 35%, and changes among the
various combination protocols and time of analysis were not
significant (Figure 2A and Supplementary Data). Similarly, no
strong difference in the amount of apoptosis was observed
among most combination protocols tested, except when VNB
was administered 48h before cryotherapy (Figure 2B and
Supplementary Data). In this sequential treatment protocol, the
amount of apoptotic cells was significantly enhanced after 48h
of combined treatment, indicating heightened apoptotic activities
in these tumours.
Molecular signalling of apoptosis
To further investigate the molecular signalling of apoptosis in
these tumours, attention was focused on Bcl-2 family members.
First, we undertook QRT–PCR and evaluated the relative mRNA
expression level of some proapoptotic members, including the
BH3-only Puma, Noxa and Bim-EL, and multidomain Bax
members. Strikingly, the expression of Puma, Noxa and Bim-EL
mRNAs increased significantly 24h and 48h post-treatment in the
sequential combination schedule, where VNB was given 48h
before cryotherapy (Figure 3A and Supplementary Data). The
kinetics of expression of these genes were correlated with the
augmented amount of apoptotic cells seen in tumours treated with
this sequential combination schedule (Figure 2B). Messenger RNA
levels of Bax and of the antiapoptotic Bcl-xL (Figure 3B) and Bcl-2
(data not shown) did not change dramatically among all tumours
tested, whereas Mcl-1 mRNA expression showed a small yet
significant increase, but at a much lower level than the BH3-only
Puma, Noxa and Bim-EL (Figure 3B and Supplementary Data).
These observations were confirmed by immunohistochemical
staining analysis, where elevated expression of Puma, Noxa and
Bim, but not Bax proteins could be easily visualised in tumour
samples obtained 48h post-treatment from mice treated with
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Figure 1 Kinetics of tumour growth after individual, simultaneous and
sequential combination of cryotherapy and VNB treatment in human A549
lung adenocarcinoma xenograft-bearing SCID mice. Relative tumour
volumes (y axis) were measured as described in Materials and Methods
at various times (x axis) after the end of treatments. Points and vertical bars
represent the means±s.e.m. of three independent experiments (three
mice). Statistical analyses are provided in Supplementary Data.
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sVNB, 48h before cryotherapy, compared with untreated or single
agent-treated mice (Figure 4).
DISCUSSION
The idea of combining cryosurgery and chemotherapy in cancer
treatment is not novel, but their optimisation needs further
evaluation. The first study was reported by Benson in 1975 when
he showed, in patients with oral cancer, that 5-FU was more
efficient when administered after cryotherapy, with its increased
accumulation in tumours immediately after cryosurgery (Benson,
1975). Later, Ikekawa et al (1985) confirmed, in a model of
melanoma cells grafted into mice, that some drugs are trapped
rapidly in tumours immediately after cryosurgery. This drug-
trapping effect was observed only when the drugs were injected
after cryosurgery because of microcirculation disturbance and
particularly local vascular stasis induced with freezing. Indeed, it is
well documented that cryotherapy elicits two major effects, a
physical effect, which is immediate and known as ‘direct cell
injury’, corresponding to the formation of ice crystals and a
vascular effect, which is mostly delayed (Gage and Baust, 1998).
Similarly, Homasson et al (1992) observed increased bleomycin
uptake (about 30%) in tumours when it was injected
2–6h after cryosurgery in patients with inoperable lung cancer.
More recently, in vitro studies have reported such a benefit of
combined treatments, but some discrepancies appeared with the
sequence of treatment. For instance, Clarke et al (1999, 2004)
found that chemotherapy was more efficient when followed by
cryosurgery in a model of renal carcinoma cells. Indeed, they
documented that simultaneous 5-FU addition or administration 2
days after cryotherapy resulted in synergistic lethality, although
many cells survived these treatments. However, when the cells
were treated with 5-FU 2 days before cryosurgery, there was an
apparent complete loss of cell viability. We have previously shown
increased cell death after cryosurgery followed by chemotherapy in
a model of A549 lung adenocarcinoma cells in SCID mice (Forest
et al, 2005a, b; Forest et al, 2006). To optimise the efficiency of
these combination treatments, we now report the effects of
different administration schedules on tumour growth, cell death
induction and apoptosis signalling. Our data suggest that 48h
sequential rather than simultaneous cryotherapy with VNB
enhances the tumour response, with no significant difference seen
within the sequence of administration. Our data also show that a
24h sequential cryotherapy with VNB does not statistically give
more benefit than simultaneous therapies, although some indivi-
dual mice did respond well. In addition, our data argue that VNB
administration 48h before cryotherapy will provoke apoptosis
more efficiently in these tumours, an effect associated with strong
activation of the BH3-only Puma, Noxa and Bim.
It is established that cryosurgery, in addition to necrosis, could
trigger apoptosis, and a few studies have implicated the mito-
chondrial pathway of apoptosis (Hanai et al, 2001; Baust et al,
2004). Clarke et al (2004) showed that freezing and chemotherapy
differentially activated Bcl-2 family members in a human prostate
cancer cell line. Freezing resulted in Bcl-2 upregulation,
whereas chemotherapy triggered increased Bax expression.
Freezing-induced Bcl-2 upregulation could be prevented by the
addition of 5-FU or cisplatin. Yang et al (2003) further confirmed
that cryo-ended apoptosis was associated with mitochondrial
dysfunction in four human colorectal cancer cell lines with
variations in the induction of the antiapoptotic Bcl-2 and Bcl-xL,
and the proapoptotic Bax, Bcl-xS, Bad and Bak proteins.
Nevertheless, the Bcl-2/Bax protein ratio was inversely correlated
with the apoptotic rate, an effect independent of p53 status in
these lines.
In our study, despite variations among mice, no apparent
differences in the amount of necrosis or apoptosis were observed
among most combination protocols tested, except in the sequential
treatment schedule where VNB was administered 48h before
cryotherapy. In this sequential treatment schedule, the number of
apoptotic cells was significantly augmented 48h-post combined
treatment, and correlated with heightened expression of the BH3-
only Puma, Noxa and Bim, at both the mRNA and protein levels.
No significant change in Bax, Bcl-xL and Bcl-2 mRNA expression
was evident, whereas Mcl-1 expression increased only slightly to a
much lower level than BH3-only mRNAs. Strikingly, no significant
change in gene expression was seen in tumour samples from mice
subjected to other protocols, although some benefit was apparent
on tumour growth. Different hypotheses will be tested in future
studies. First, we focused our expression study on a few Bcl-2
members, and investigation into other family members should be
conducted. Second, other signalling pathway of apoptosis should
be explored, including cell death receptor pathways. Finally, the
importance of cytostatic effects, including growth arrest and
premature senescence (Schmitt, 2007) where tumour cells are not
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Figure 2 Kinetics of cell death after individual, simultaneous and
sequential combination of cryotherapy and VNB treatment. (A) The
relative percentage of necrotic area (y axis) was determined in tumour
samples collected at various times (x axis) after the end of treatments by
Haematoxylin–Eosin–Saffron staining. Points and vertical bars represent
the means±s.e.m. of three independent samples (three mice). C means
untreated control tumours at time 0. (B) The amount of apoptotic cells is
reported as volume values (intensity (%) area (mm
2)) determined after
immunohistochemical staining (as described in Materials and Methods) in
tumour samples collected at various times (x axis) after the end of
treatments. Points and vertical bars represent the means±s.e.m. of three
independent samples (three mice). C means untreated control tumours at
time 0. Statistical analyses are provided in Supplementary Data.
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sdying, but stop proliferating, needs further attention. Our data
revealed that TVs after the 48h sequential schedule are nearly
similar to TVs at day 0 of untreated mice, suggesting that cytostatic
effects are important in this model.
Variations among individual mice were also observed in this
study. Indeed, individual mice will have their own intrinsic
variations and responses to treatment, but in vivo tumour models
also have their own experimental challenges. It has been well
established that tissue response to freezing is inhomogeneous as
the influence of cold is spherical and decreases as a function of
cryoprobe impact site. While producing tumour sample sections
for microscopy, although special care was taken to cut them along
the axis of the cryoprobe impact site, sample preparations could
vary. Quantitative real-time PCR was also carried on tissues
extracted along the same axis. Thus, a global analysis of the
tumours rather than different areas relative to the cryoprobe
impact site was carried out. Finally, with an in vivo model, tissue
samples are collected at specific, fixed time points. It is, therefore,
hard to investigate in detail a dynamic event or process. Perhaps,
apoptotic cell phagocytosis by neighbouring cells is very dynamic
and rapid, erasing traces of apoptosis in some tumour samples
collected at fixed time points.
In conclusion, our data indicate that 48h sequential rather than
simultaneous or individual administration of cryotherapy with
VNB in future cancer cryochemotherapy schedules enhances the
tumour response. Our results also argue that VNB administration
48h before cryotherapy will provoke apoptosis more efficiently in
these tumours, an effect associated with Puma, Noxa and Bim-EL
upregulation. However, we cannot extent our findings to other
lung cancer models (epidermoid carcinoma instead of adeno-
carcinoma) or predict whether the same signalling pathways would
be triggered with other chemotherapeutic agents (for instance if we
use cisplatin instead of VNB). Therefore, further investigations are
required for a better understanding of cryotherapy mechanisms of
action and its biological actions at the tissue, cellular and
molecular levels; but this study can represent a helpful starting
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Supplementary Data.
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spoint. Better knowledge of the pathways of cell death, growth
arrest and premature senescence induced by cryotherapy in
combination with chemotherapy will lead to further optimisation
of these combination schedules to achieve a better clinical
response.
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